公司資料
Monopar 股價、新聞與催化劑
- 股票代碼:
- MNPR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
102.70 USD (+1.23%)
收盤價
最後更新: 2026年9月17日
410M USD
市值
股價為何變動
截至 2026年9月17日，MNPR 上漲 1.23%，收於 $102.70。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications. Its narrative is built around using a concentrated pipeline to create value in high-unmet-need settings.
所在地與產業分類
Monopar is headquartered in the United States and listed on NASDAQ. It sits in small-cap specialty biopharma.
商業模式特徵
The company depends on clinical progress, strategic prioritization, and capital management across a narrow program set. Investors typically watch proof-of-concept data and financing runway.
生技產業定位
Monopar occupies a catalyst-sensitive niche within biotech. The stock is driven by whether its focused development approach can produce clear differentiated value.
未來催化劑
- What matters most for Monopar from here is ALXN1840 and tiomolibdate choline. That matters because the company is now talking about NDA Submission on Track for Mid-2026 In April 2026, Monopar presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) at.... That is the piece most likely to shape sentiment in the near term.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。